G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
RESEARCH TRIANGLE PARK, N.C., Jan. 02, 2024 (GLOBE NEWSWIRE) — G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the grant of inducement stock options exercisable for 6,300 shares of G1’s common stock and 3,000 restricted stock units (RSUs) to three hired employees under the Amended and Restated G1 Therapeutics, Inc. 2021 Inducement Equity Incentive Plan (the “Amended and Restated 2021 Plan”). These equity awards were granted as an inducement material to the new employee becoming an employee of G1 in accordance with Nasdaq Listing Rule 5635(c)(4).
Related news for (GTHX)
- pharmacosmos group and g1 therapeutics announce expiration of hart-scott-rodino waiting period
- G1 Therapeutics Provides Corporate Update at the 42nd Annual J.P. Morgan Healthcare Conference
- G1 Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
- G1 Therapeutics Presents New Post Hoc Analyses Indicating That Patients Who Previously Received Trilaciclib Have Improved Overall Survival with Subsequent Anticancer Therapy